HB 4101, the Cancer Drug Parity Act of 2025, would amend ERISA to require group health plans and health insurance coverage offered with those plans to treat oral anticancer drugs no less favorably than anticancer drugs administered by a health care provider. In practical terms, if a plan covers infused or injected cancer medications, it would have to apply comparable cost-sharing to FDA-approved, patient-administered oral anticancer medications when prescribed as medically necessary or clinically appropriate by the treating physician.
The bill also prohibits insurers and plans from complying in ways that would indirectly raise patient costs, such as reclassifying benefits, increasing out-of-pocket expenses, or imposing more restrictive limits on oral cancer drugs than on comparable provider-administered drugs. It preserves the ability of plans to use prior authorization and other utilization management tools, and it does not require patients to switch to oral drugs. The bill would take effect for plan years beginning on or after January 1, 2026, and it directs the Government Accountability Office to study the law’s impact on out-of-pocket costs and access to oral cancer medications within two years of enactment.
Impact
If enacted, the bill would add a new ERISA section establishing federal parity rules for cost-sharing on oral anticancer medications in employer-sponsored group health plans and related coverage. It would affect plan design, pharmacy and medical benefit structures, and insurer cost-sharing practices by limiting higher deductibles, copays, coinsurance, or other out-of-pocket charges for oral cancer drugs when compared with infused or injected cancer therapies. The bill also preserves stronger state laws, meaning states could continue to enforce more protective coverage requirements for oral anticancer drugs.
Sentiment
The available context suggests generally strong bipartisan and pro-patient support for the bill. The measure was introduced by a cross-party group of House members, which is consistent with a consensus approach to reducing financial barriers for cancer patients. No committee transcript or vote record is provided, so there is no evidence in the supplied materials of formal opposition or divided voting.
Contention
The main policy issue is how far the parity requirement should go and how it interacts with plan management tools. The bill requires equalized cost-sharing for oral anticancer drugs, but it explicitly allows prior authorization and other utilization controls, which may be important to insurers and plan sponsors. Another point of potential contention is cost: employers and insurers may be concerned that requiring lower patient cost-sharing for oral drugs could increase plan spending, while patient advocates are likely to emphasize improved access and reduced out-of-pocket burden. The bill also leaves room for state laws that provide greater protections, which could matter in states with existing oral chemotherapy parity statutes.